MIT Researchers Develop Injectable Nanodevices for Drug-Resistant Glioblastoma, Offering New Strategy for Infiltrative Tumors by Crossing Blood-Brain Barrier and Evading Immune System

September 13, 2026

Medical Xpress USA

Overview

MIT researchers have developed injectable nanodevices with the potential to provide effective treatment for drug-resistant glioblastoma (GBM). Previous studies demonstrated these nanodevices safely integrate with living cells, evade immune system attack, and readily cross the blood-brain barrier. This breakthrough opens new strategies for delivering therapeutics effectively to highly infiltrative brain tumors, which are challenging for conventional treatments, offering hope to patients with this intractable cancer.

In Depth

Key Findings

A research team at the Massachusetts Institute of Technology (MIT) has successfully developed injectable nanodevices with the potential to offer a revolutionary treatment approach for drug-resistant glioblastoma (GBM), a particularly challenging form of brain cancer. This innovative nanotechnology device has previously demonstrated its ability to safely integrate with living cells, cleverly evade attacks from the immune system, and readily traverse the blood-brain barrier (BBB), the brain’s protective shield. This technology represents a significant leap forward, enabling effective drug delivery even to highly infiltrative brain tumors that have been extremely difficult to access with conventional treatments.

Technical / Clinical Details

Glioblastoma is one of the most aggressive brain tumors, and due to its infiltrative nature and drug resistance, existing therapies offer limited patient outcomes. Key challenges include the inability of effective anti-cancer drugs to cross the blood-brain barrier and adequately reach tumor cells within the brain, as well as the tumor’s propensity to develop drug resistance. The nanodevice developed by MIT possesses the following critical properties:

Blood-Brain Barrier Penetration: Optimized nanoscale size and surface properties allow the device to efficiently cross the blood-brain barrier, which typically blocks most drugs, to reach tumor sites deep within brain tissue.
Immune Evasion Capability: Highly biocompatible materials and surface modifications enable the device to avoid rapid elimination by the body’s immune system, extending its residence time at the tumor site and maximizing therapeutic agent exposure.
Integration with Living Cells: The nanodevice’s ability to safely coexist with living cells without affecting their function suggests the potential for long-term treatment and repeated dosing.
Function as a Drug Delivery System: This device is designed to encapsulate specific anti-cancer drugs or gene therapy agents and selectively deliver them to tumor cells, serving as a platform especially useful for targeting new therapeutics aimed at overcoming drug resistance.

This technology also holds promise for solving drug delivery challenges in other neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, in addition to glioblastoma.

Background & Industry Context

Brain tumors, particularly glioblastoma, are associated with a very poor prognosis and short survival times, representing an intractable cancer. Standard treatments, including surgery, radiation therapy, and chemotherapy, have limitations, with the acquisition of drug resistance being a major factor in recurrence. Nanomedicine has long been investigated as a promising approach to overcome the blood-brain barrier challenge and enable selective drug delivery to tumors. The achievement of such a breakthrough by a world-leading research institution like MIT strongly suggests that nanotechnology will play a pivotal role in addressing unmet medical needs. This research marks a critical step in shaping the future of personalized and precision medicine.

Strategic Significance & Outlook

The success of these injectable nanodevices has the potential to fundamentally transform treatment strategies for drug-resistant glioblastoma. Rapid progression to detailed preclinical and subsequent human clinical trials to further confirm safety and efficacy is anticipated. If clinical translation is realized, this could become a revolutionary therapy dramatically improving the prognosis and quality of life for glioblastoma patients. This nanotechnology-based therapy is expected to usher in a new era of drug delivery in brain disease treatment, offering hope to many patients suffering from severe and intractable conditions.

Source: https://news.mit.edu/2026/injectable-nanodevices-could-provide-effective-treatment-drug-resistant-glioblastoma-0909

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.